ORYX GmbH & Co. KG
ORYX reports positive clinical evidence with oncolytic virus ParvOryx in combination with immuno-oncology drugs
DGAP-News: ORYX GmbH & Co. KG / Key word(s): Study results Press Release ORYX reports positive clinical evidence with oncolytic virus ParvOryx in combination with immuno-oncology drugs Seven patients suffering from glioblastoma multiforme (GBM) who had experienced a second relapse following treatment with ParvOryx in a completed Phase I/IIa study were treated with ParvOryx plus Avastin(R) following surgery. In the seven ParvOryx/Avastin(R)-treated patients, median overall survival (mOS) was prolonged to 25.9 months compared to the ParvOryx monotherapy study mOS (15.9 months). Additionally, nine GBM patients with either primary, diffuse primary, single recurrent or double recurrent GBM were treated with ParvOryx in combination with an immune checkpoint inhibitor alone (1) or in combination with Avastin(R) and an immune checkpoint inhibitor (8) without prior surgery. All nine patients responded with objective tumor regression already after 6-8 weeks. The tumor load was reduced by 45-96% as measured by RANO (Response Assessment in Neuro-Oncology) criteria. Follow-up is ongoing. Two patients relapsed (26 and 47 weeks) after virotherapy, while receiving constant treatment with Avastin(R) and an immune checkpoint inhibitor. Treatment with ParvOryx together with the resumption of combination therapy with Avastin(R) and the checkpoint inhibitor led to rapid regression of the tumor mass and disease control. Dr. Michael Dahm, ORYX’s Chief Medical Officer, said: “Although these data are preliminary and uncontrolled, they are highly encouraging. We look forward to evaluating ParvOryx in combination with Avastin(R) or with Avastin(R) plus an immune checkpoint inhibitor in a controlled clinical trial setting.” About ParvOryx ParvOryx successfully completed a Phase I/IIa trial to treat glioblastoma multiforme in 18 patients with recurrent or progressive disease. A dose-escalation Phase I/IIa pilot study for the treatment of metastatic pancreatic cancer with ParvOryx monotherapy is currently ongoing, with topline data expected in Q4 2017. About ORYX For further information, please contact:
Avastin(R) is a registered trademark of Genentech, Inc., a member of the Roche Group.
23.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |